Lung Cancer Trials Ask AI to find trials
CompletedPhase 2NCT01671332
Official study title

Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

Study summary

The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedDocetaxel and Suramin

Plus 1 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 12, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?University of Wisconsin, Madison

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
University of Wisconsin, Madison
Interventions being studied
Drug: Docetaxel; Drug: Suramin; Drug: Docetaxel
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Pathologically proven diagnosis of non-small cell lung cancer
  • Documented disease progression after first-line chemotherapy for non-small cell lung cancer
  • Stable and treated CNS metastasis is allowed
  • Radiation must be completed at least 2 weeks prior to starting protocol treatment
  • Major surgery must be completed at least 4 weeks prior to starting protocol treatment
  • ECOG performance status 0-2
  • Sexually active patients must use adequate contraception
  • Adequate bone marrow function
  • Adequate renal function
  • Adequate liver function
Reasons someone may not be able to joinExclusion criteria
  • Severe hypersensitivity reaction to docetaxel
  • Pre-existing grade 3 or 4 neuropathy
  • Women who are pregnant or breastfeeding
  • Uncontrolled intercurrent illness
  • Receipt of 3 or more prior chemotherapy regimens

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of Wisconsin Carbone Comprehensive Cancer CenterMadison, Wisconsin
  • Medical College of WisconsinMilwaukee, Wisconsin

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 12, 2020. Always confirm current availability with the study team.

View original record ↗